Multimonth controlled small molecule release from biodegradable thin films

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 33, 2014, Pages 12175-12180

  Hsu, Bryan B ^a,b   Park, Myoung Hwan ^c   Hagerman, Samantha R ^b   Hammond, Paula T ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c Sahmyook University   (South Korea)

Author keywords

NSAID; Polyelectrolyte multilayers; Polymer prodrug

Indexed keywords

CYCLOOXYGENASE 1; DICLOFENAC; NANOFILM; POLYMER;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; NANOANALYSIS; PRIORITY JOURNAL; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; SUSTAINED RELEASE PREPARATION;

NSAID; POLYELECTROLYTE MULTILAYERS; POLYMER PRODRUG;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOCOMPATIBLE MATERIALS; DICLOFENAC; DRUG DELIVERY SYSTEMS; POLYMERS;

EID: 84906302983     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1323829111     Document Type: Article

References (71)

1. Connolly LE, Edelstein PH, Ramakrishnan L (2007) Why is long-term therapy required to cure tuberculosis? PLoS Med 4(3):e120.
2. Konstan MW, Schluchter MD, Xue W, Davis PB (2007) Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 176(11):1084-1089. (Pubitemid 350223754)
3. Kroon F, Landewé R, Dougados M, van der Heijde D (2012) Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 71(10):1623-1629.
4. Hazirolan D, Pleyer U (2013) Think global - act local: Intravitreal drug delivery systems in chronic noninfectious uveitis. Ophthalmic Res 49(2):59-65.
5. Blackwell D, Clarke T (2013) Percentage of adults aged ≥18 years who often had pain in the past 3 months, by sex and age group - National Health Interview Survey, United States 2010-2011. MMWR Morb Mortal Wkly Rep 62(17):342.
6. Institute of Medicine (2011) Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research (National Academies Press, Washington, DC).
7. Zhang W, et al. (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18(4):476-499.
8. Franceschi M, et al. (2008) Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1756 patients. Drug Saf 31(6):545-556. (Pubitemid 351693687)
9. Richette P, et al. (2011) Comparison of general practitioners and rheumatologists' prescription patterns for patients with knee osteoarthritis. BMC Musculoskelet Disord 12:72.
10. Siepmann J, Siegel RA, Rathbone MJ, eds (2012) Fundamentals and Applications of Controlled Release Drug Delivery (Springer, New York).
11. Tugwell PS, Wells GA, Shainhouse JZ (2004) Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. J Rheumatol 31(10):2002-2012. (Pubitemid 39336727)
12. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG (1979) The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 16(6):405-410. (Pubitemid 10173752)
13. Richter A, Anton SE, Koch P, Dennett SL (2003) The impact of reducing dose frequency on health outcomes. Clin Ther 25(8):2307-2335. (Pubitemid 37076322)
14. Fredenberg S, Wahlgren M, Reslow M, Axelsson A (2011) The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems - a review. Int J Pharm 415(1-2):34-52.
15. Klose D, Siepmann F, Elkharraz K, Krenzlin S, Siepmann J (2006) How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int J Pharm 314(2):198-206.
16. Goldberg M, Langer R, Jia X (2007) Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed 18(3):241-268. (Pubitemid 46403135)
17. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM (1999) Polymeric systems for controlled drug release. Chem Rev 99(11):3181-3198. (Pubitemid 129583051)
18. Del Amo EM, Urtti A (2008) Current and future ophthalmic drug delivery systems: A shift to the posterior segment. Drug Discov Today 13(3-4):135-143.
19. Sprintz M, et al. (2011) Nanomedicine: Ushering in a new era of pain management. Eur J Pain Suppl 5(S2):317-322.
20. Hyder MN, Shah NJ, Hammond PT (2012) Design and translation of nanolayer assembly processes: electrochemical energy to programmable pharmacies. Multilayer Thin Films, eds Decher G, Schlenoff JB (Wiley-VCH, Weinheim, Gemany), 2nd Ed.
21. Moskowitz JS, et al. (2010) The effectiveness of the controlled release of gentamicin from polyelectrolyte multilayers in the treatment of Staphylococcus aureus infection in a rabbit bone model. Biomaterials 31(23):6019-6030.
22. Shukla A, Avadhany SN, Fang JC, Hammond PT (2010) Tunable vancomycin- releasing surfaces for biomedical applications. Small 6(21):2392-2404.
23. Kim B-S, Park SW, Hammond PT (2008) Hydrogen-bonding layer-by-layer- assembled biodegradable polymeric micelles as drug delivery vehicles from surfaces. ACS Nano 2(2):386-392. (Pubitemid 351585956)
24. Smith RC, Riollano M, Leung A, Hammond PT (2009) Layer-by-layer platform technology for small-molecule delivery. Angew Chem Int Ed Engl 48(47):8974-8977.
25. Shukla A, Fuller RC, Hammond PT (2011) Design of multi-drug release coatings targeting infection and inflammation. J Control Release 155(2):159-166.
26. Chluba J, et al. (2001) Peptide hormone covalently bound to polyelectrolytes and embedded into multilayer architectures conserving full biological activity. Biomacromolecules 2(3):800-805. (Pubitemid 32894635)
27. Schultz P, et al. (2005) Polyelectrolyte multilayers functionalized by a synthetic analogue of an anti-inflammatory peptide, α- MSH, for coating a tracheal prosthesis. Biomaterials 26(15):2621-2630. (Pubitemid 39600714)
28. Ochs CJ, Such GK, Yan Y, van Koeverden MP, Caruso F (2010) Biodegradable click capsules with engineered drug-loaded multilayers. ACS Nano 4(3):1653-1663.
29. Fini A, Fazio G, Feroci G (1995) Solubility and solubilization properties of non-steroidal anti-inflammatory drugs. Int J Pharm 126(1-2):95-102. (Pubitemid 26015628)
30. Bonina FP, et al. (2001) In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur J Pharm Sci 14(2):123-134.
31. Li C, et al. (1998) Complete regression of well-established tumors using a novel watersoluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res 58(11):2404-2409. (Pubitemid 28252701)
32. Hao AJ, et al. (2006) Degradation kinetics of fluorouracil-acetic-acid- dextran conjugate in aqueous solution. Drug Dev Ind Pharm 32(6):757-763. (Pubitemid 44181202)
33. Larsen C, Johansen M (1985) Macromolecular prodrugs, 1: Kinetics and mechanism of hydrolysis of O-benzoyl dextran conjugates in aqueous buffer and in human plasma. Int J Pharm 27(2-3):205-218. (Pubitemid 16218672)
34. Larsen C (1989) Macromolecular prodrugs, 12: Kinetics of release of naproxen from various polysaccharide ester prodrugs in neutral and alkaline-solution. Int J Pharm 51(3):233-240.
35. Wu C, Xie J, Branford-White C, Quan J, Zhu L (2011) In vitro controlled release of polymeric drug-saccharide conjugates with ketoprofen, ibuprofen, and naproxen pendants. J Appl Polym Sci 121(3):1654-1660.
36. Rajewski LG, Stinnett AA, Stella VJ, Topp EM (1992) Enzymatic and nonenzymatic hydrolysis of a polymeric prodrug - hydrocortisone esters of hyaluronic acid. Int J Pharm 82(3):205-213.
37. McCoy CP, Morrow RJ, Edwards CR, Jones DS, Gorman SP (2007) Neighboring group-controlled hydrolysis: Towards "designer" drug release biomaterials. Bioconjug Chem 18(1):209-215. (Pubitemid 46146012)
38. Kondo S, Murase K, Kuzuya M (1994) Mechanochemical solid-state polymerization, 7: The nature of hydrolysis of novel polymeric prodrugs prepared by mechanochemical copolymerization. Chem Pharm Bull (Tokyo) 42(12):2412-2417.
39. Jo YS, Gantz J, Hubbell JA, Lutolf MP (2009) Tailoring hydrogel degradation and drug release via neighboring amino acid controlled ester hydrolysis. Soft Matter 5(2):440-446.
40. Heller J, Helwing RF, Baker RW, Tuttle ME (1983) Controlled release of water-soluble macromolecules from bioerodible hydrogels. Biomaterials 4(4):262-266.
41. Schoenmakers RG, van de Wetering P, Elbert DL, Hubbell JA (2004) The effect of the linker on the hydrolysis rate of drug-linked ester bonds. J Control Release 95(2):291-300. (Pubitemid 38230043)
42. Kataoka K, Harada A, Nagasaki Y (2001) Block copolymer micelles for drug delivery: Design, characterization and biological significance. Adv Drug Deliv Rev 47(1):113-131. (Pubitemid 32209236)
43. Deo P, Deo N, Somasundaran P, Jockusch S, Turro NJ (2005) Conformational changes of pyrene-labeled polyelectrolytes with pH: Effect of hydrophobic modifications. J Phys Chem B 109(44):20714-20718. (Pubitemid 41698330)
44. Lee AS, Gast AP, Bütün V, Armes SP (1999) Characterizing the structure of pH-dependent polyelectrolyte block copolymer micelles. Macromolecules 32(13):4302-4310.
45. Decher G (1997) Fuzzy nanoassemblies: Toward layered polymeric multicomposites. Science 277(5330):1232-1237.
46. Porcel C, et al. (2006) From exponential to linear growth in polyelectrolyte multilayers. Langmuir 22(9):4376-4383.
47. Dos A, Schimming V, Tosoni S, Limbach H-H (2008) Acid-base interactions and secondary structures of poly-L-lysine probed by 15N and 13C solid-state NMR and ab initio model calculations. J Phys Chem B 112(49):15604-15615.
48. Myer YP (1969) The pH-induced helix-coil transition of poly-L-lysine and poly-L-glutamic acid and the 238-mμ dichroic band. Macromolecules 2(6):624-628.
49. Lavalle P, et al. (2002) Comparison of the structure of polyelectrolyte multilayer films exhibiting a linear and an exponential growth regime: An in situ atomic force microscopy study. Macromolecules 35(11):4458-4465. (Pubitemid 34566348)
50. Picart C, et al. (2002) Molecular basis for the explanation of the exponential growth of polyelectrolyte multilayers. Proc Natl Acad Sci USA 99(20):12531-12535.
51. Song Z, et al. (2009) Layer-by-layer buildup of poly(L-glutamic acid)/chitosan film for biologically active coating. Macromol Biosci 9(3):268-278.
52. Shiratori SS, Rubner MF (2000) pH-dependent thickness behavior of sequentially adsorbed layers of weak polyelectrolytes. Macromolecules 33(11):4213-4219.
53. Wang QZ, et al. (2006) Protonation constants of chitosan with different molecular weight and degree of deacetylation. Carbohydr Polym 65(2):194-201. (Pubitemid 44107503)
54. Huang X, Brazel CS (2001) On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release 73(2-3):121-136. (Pubitemid 32539245)
55. Allison SD (2008) Analysis of initial burst in PLGA microparticles. Expert Opin Drug Deliv 5(6):615-628.
56. Pitt CG, Cha Y, Shah SS, Zhu KJ (1992) Blend of PVA and PGLA: Control of the permeability and degradability of hydrogels by blending. J Control Release 19(1-3):189-199.
57. Fini A, Fazio G, Rabasco AM, Hervas MJF (1994) Self-association properties of diclofenac. Farmaco 49(2):141-146. (Pubitemid 24125168)
58. Li Y, Kwon GS (2000) Methotrexate esters of poly(ethylene oxide)-block-poly(2-hydroxyethyl-L-aspartamide), part I: Effects of the level of methotrexate conjugation on the stability of micelles and on drug release. Pharm Res 17(5):607-611. (Pubitemid 30416400)
59. Thierry B, et al. (2005) Delivery platform for hydrophobic drugs: Prodrug approach combined with self-assembled multilayers. J Am Chem Soc 127(6):1626-1627. (Pubitemid 40229134)
60. Tunçay M, et al. (2000) Diclofenac sodium incorporated PLGA (50:50) microspheres: Formulation considerations and in vitro/in vivo evaluation. Int J Pharm 195(1-2):179-188. (Pubitemid 30089502)
61. Liu D, et al. (2010) Solid lipid nanoparticles for transdermal delivery of diclofenac sodium: Preparation, characterization and in vitro studies. J Microencapsul 27(8):726-734.
62. Zhang J, Fredin NJ, Janz JF, Sun B, Lynn DM (2006) Structure/property relationships in erodible multilayered films: Influence of polycation structure on erosion profiles and the release of anionic polyelectrolytes. Langmuir 22(1):239-245. (Pubitemid 43063544)
63. Craig M, Bordes R, Holmberg K (2012) Polypeptide multilayer self-assembly and enzymatic degradation on tailored gold surfaces studied by QCM-D. Soft Matter 8(17):4788-4794.
64. Picart C, et al. (2005) Controlled degradability of polysaccharide multilayer films in vitro and in vivo. Adv Funct Mater 15(11):1771-1780. (Pubitemid 41609636)
65. Jessel N, et al. (2003) Bioactive coatings based on a polyelectrolyte multilayer architecture functionalized by embedded proteins. Adv Mater 15(9):692-695.
66. Serizawa T, Yamaguchi M, Akashi M (2002) Enzymatic hydrolysis of a layer-by-layer assembly prepared from chitosan and dextran sulfate. Macromolecules 35(23):8656-8658. (Pubitemid 35359200)
67. Heuberger R, Sukhorukov G, Vörös J, Textor M, Möhwald H (2005) Biofunctional polyelectrolyte multilayers and microcapsules: Control of non-specific and bio-specific protein adsorption. Adv Funct Mater 15(3):357-366. (Pubitemid 40430427)
68. Wong SY, et al. (2012) Drastically lowered protein adsorption on microbicidal hydrophobic/ hydrophilic polyelectrolyte multilayers. Biomacromolecules 13(3):719-726.
69. Sidhu RS, Lee JY, Yuan C, Smith WL (2010) Comparison of cyclooxygenase-1 crystal structures: Cross-talk between monomers comprising cyclooxygenase-1 homodimers. Biochemistry 49(33):7069-7079.
70. Galmier MJ, et al. (2005) Identification of degradation products of diclofenac by electrospray ion trap mass spectrometry. J Pharm Biomed Anal 38(4):790-796.
71. Kato M, Nishida S, Kitasato H, Sakata N, Kawai S (2001) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: Investigation using human peripheral monocytes. J Pharm Pharmacol 53(12):1679-1685. (Pubitemid 34044256)